RxDoctor Payments Data

Carlos Garcia Monterroso, MD

Internal Medicine · San Antonio, TXNPI 1114545290

Payments from drug & device makers

$2,059in general payments, 2019–2025

Across 70 payments — averaging $29.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$473
  • Lilly USA, LLC$434
  • Bayer$168
  • Merck$140
  • GSK$136
  • Dexcom, Inc.$125
  • plus $583 from 11 others

What the payments were for

  • Food & beverage$2,059100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,059 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$39,160
Medicare patients
126
Services billed
635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide133$177,346
JardianceEmpagliflozin88$124,443
MounjaroTirzepatide69$81,549
LinzessLinaclotide37$37,954
TrulicityDulaglutide14$34,291
FarxigaDapagliflozin Propanediol23$33,197
EliquisApixaban20$31,329
Trijardy XrEmpaglifloz/Linaglip/Metformin13$22,409
JanuviaSitagliptin Phosphate13$21,703
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$21,262
XareltoRivaroxaban22$20,947
GemtesaVibegron20$20,155
Tresiba Flextouch U-100Insulin Degludec14$7,898
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$7,218
Lantus SolostarInsulin Glargine,hum.Rec.Anlog74$7,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$473$177,346133 claims
Boehringer IngelheimJardiance, Trijardy Xr$43$146,852101 claims
Lilly USA, LLCMounjaro, Trulicity$434$115,84083 claims
AbbVieLinzess$32$37,95437 claims
AstraZenecaFarxiga$84$33,19723 claims
PfizerEliquis$17$31,32920 claims
GSKTrelegy Ellipta, Anoro Ellipta$136$28,48127 claims
MerckJanuvia$140$21,70313 claims
Sumitomo Pharma America, Inc.Gemtesa$57$20,15520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →